Ipsen, Skyhawk Therapeutics To Develop RNA-Modulating Molecules For Rare Neurological Disorders
(RTTNews) – French biopharmaceutical company Ipsen SA (IPSEY) and Skyhawk Therapeutics announced an exclusive worldwide collaboration aimed at discovering and developing novel small molecules capable of modulating RNA for rare neurological diseases.